| Mar'18 | Mar'17 | Mar'16 | Mar'15 | Mar'14 | Mar'13 | Mar'12 |
|---|---|---|---|---|---|---|
Net revenues | ||||||
563,932 | 435,713 | 370,812 | 290,781 | 202,304 | 133,871 | - |
Net revenues | ||||||
- | - | - | - | - | - | 93,713 |
Cost of revenues | ||||||
325,656 | 262,134 | 210,909 | 154,943 | 106,405 | 71,079 | 49,506 |
Gross profit | ||||||
238,276 | 173,579 | 159,903 | 135,838 | 95,899 | 62,792 | 44,207 |
Operating expenses: | ||||||
Selling and marketing expenses | ||||||
96,594 | 74,304 | 64,763 | 41,059 | 28,879 | 18,486 | 14,005 |
General and administrative expenses (including share-based compensation expenses of $1,949, $1,941 and $34,822 in 2016, 2017 and 2018, respectively) | ||||||
126,255 | 82,783 | 65,422 | 52,331 | 32,053 | 23,447 | 14,756 |
Research and development expenses | ||||||
3,055 | 3,194 | 3,716 | 1,401 | 1,603 | 1,270 | 748 |
Write-off of leasehold improvement | ||||||
- | - | - | - | - | - | 309 |
Total operating expenses | ||||||
225,904 | 160,281 | 133,901 | 94,791 | 62,535 | 43,203 | 29,818 |
Income from operations | ||||||
12,372 | 13,298 | 26,002 | 41,047 | 33,364 | 19,589 | 14,389 |
Loss from forward contracts | ||||||
- | - | - | -8 | 57 | - | - |
Interest expense | ||||||
20,191 | 13,880 | 4,603 | 2,466 | 1,331 | 1,106 | 159 |
Interest income | ||||||
382 | 939 | 785 | 699 | 93 | 100 | 101 |
Other income | ||||||
- | - | 1,874 | 883 | - | - | - |
Income/(loss)before provision for income taxes and gain/(loss) from equity method investments | ||||||
-7,437 | 357 | 24,058 | 40,155 | 32,183 | 18,583 | 10,392 |
Income before provision for income taxes and loss from equity method investment | ||||||
- | - | - | - | - | - | 14,331 |
Income tax expenses | ||||||
6,791 | 3,354 | 5,838 | 13,280 | 10,101 | 6,134 | 3,939 |
Income/(loss) before loss from equity method investments | ||||||
-14,228 | -2,997 | 18,220 | 26,875 | 22,082 | 12,449 | - |
Loss from equity method investments | ||||||
-2,448 | -9,547 | -1,732 | 521 | -156 | - | - |
Net income/(loss) | ||||||
-16,676 | -12,544 | 16,488 | 27,396 | 21,926 | 12,449 | 10,392 |
Less: Net income/(loss) attributable to non-controlling interest | ||||||
633 | -1,293 | -1,837 | 283 | 319 | 338 | 690 |
Net income/(loss) attributable to iKang Healthcare Group, Inc. | ||||||
-17,309 | -11,251 | 18,325 | 27,113 | 21,607 | 12,111 | 9,702 |
Deemed dividend to preferred shareholders | ||||||
- | - | - | 100 | 20,436 | 84,306 | 2,312 |
Undistributed earnings allocated to preferred shareholders | ||||||
- | - | - | 201 | 7,310 | 2,818 | - |
Undistributed earnings allocated to preferred shareholders | ||||||
- | - | - | - | - | - | 2,770 |
Net income/(loss) attributable to common shareholders of iKang Healthcare Group, Inc. | ||||||
-17,309 | -11,251 | 18,325 | 26,812 | -6,139 | -75,013 | 4,620 |
Net income/(loss) per share attributable to common shareholders of iKang Healthcare Group, Inc. | ||||||
Basic (in dollars per share) | ||||||
-0.50 | -0.33 | 0.55 | 0.82 | -0.97 | -11.22 | 0.22 |
Diluted (in dollars per share) | ||||||
-0.50 | -0.33 | 0.54 | 0.79 | -0.97 | -11.22 | 0.21 |
Weighted average shares used in calculating net (loss) income per common share | ||||||
Basic (in shares) | ||||||
34,295 | 34,060 | 33,583 | 32,884 | 6,340 | 6,683 | 6,599 |
Diluted (in shares) | ||||||
34,295 | 34,060 | 34,235 | 34,114 | 6,340 | 6,683 | 6,768 |